Comment Letters

  • Comment letter to the U.S. Preventive Services Task Force (USPSTF) on draft recommendation statement on breast cancer screening submitted to USPSTF on May 18, 2015.

  • Dear Ms. Kux: On behalf of the members of the Medical Imaging and Technology Alliance (MITA), we thank you for this opportunity to provide comments on FDA’s Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types, Draft Guidance. We are pleased the FDA continues to seek input for the development of strategies Read More

  • For the reasons stated below, we respectfully request that the Copyright Office oppose the inclusion of medical devices in an exemption under Proposed Class 25. Position Summary • Allowing unauthorized circumvention of TPMs in medical devices can harm patients, compromise patient privacy, and place valuable intellectual property at risk. • Permitting unauthorized circumvention for security Read More

  • RE: Docket No. NIH-2011- 0003 and RIN 0925-AA52; Clinical Trials Registration and Results Submission; Proposed Rule; Request For Comments Dear Director Collins: The Medical Imaging and Technology Alliance (MITA) is pleased to submit comments in response to the National Institutes of Health Proposed Rule and Request for Comments on Clinical Trials Registration and Results Submission. Read More

  • Dear Dr. Ritter, The Medical Imaging & Technology Alliance (MITA) would like to take this opportunity to comment on the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) recently submitted letter regarding its proposed reconfiguration of the nuclear medicine APCs for Calendar Year (CY) 2016. MITA has extensive knowledge of the substantial benefits afforded by Read More

  • RE: Washington State Health Care Authority Health Technology Assessment draft findings and decision on Functional Neuroimaging for Primary Degenerative Dementia or Mild Cognitive Impairment Dear Director Teeter: The Medical Imaging & Technology Alliance (MITA) is pleased to submit a comment on the Washington State Health Care Authority (HCA) Health Technology Assessment (HTA) Draft Findings and Read More

  • RE: Washington State Health Care Authority Health Technology Assessment draft decision on Appropriate Imaging for Breast Cancer Screening in Special Populations. Dear Director Teeter: The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Washington State Health Care Authority (HCA) Health Technology Assessment (HTA) Draft decision on Appropriate Imaging for Breast Read More

  • RE: Requests for Scientific Information: Imaging for Pretreatment Staging of Small Cell Lung Cancer Dear Dr. Kronick: The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Agency for Healthcare Research and Quality (AHRQ) Requests for Scientific Information: Imaging for Pretreatment Staging of Small Cell Lung Cancer (“Requests for Scientific Information”).1 Read More

  • MITA submitted comments to CMS on the Proposed Decision Memorandum on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT).

  • The Medical Imaging & Technology Alliance (MITA) is pleased to submit comments on the Agency for Healthcare Research and Quality (AHRQ) Draft Key Questions on Imaging for Pretreatment Staging of Small Cell Lung Carcinoma (“Draft Key Questions”).



  • Imaging Forward

    In just 20 years, medical imaging has dramatically improved health outcomes and lowered costs. Imagine what the future holds. Learn More


  • The State of Medical Imaging

    New MITA Infographic highlights the current threats to medical imaging, as well as patient-centered policy proposals. Learn More

  • Navidea

    Why I Joined MITA – Navidea Biopharmaceuticals

    Hear from Thomas Tulip, Executive Vice President and Chief Business Officer of Navidea Biopharmaceuticals, on why his organization joined MITA.

    Learn More